Norwich hospital in new MS pill trials
A Norwich hospital has been at the forefront of trials for a new pill for multiple sclerosis which has today been approved for use in the UK.
Fingolimod is the first oral treatment developed for the autoimmune disease.
Today it was given the green light by UK drug regulators and licensed as a 'second line'' treatment for patients who have failed on other medication.
Consultant neurologist Martin Lee is part of a team at the Norfolk and Norwich University Hospital which provides care for around 1,800 people with MS.
He been a lead trialist for fingolimod since 2004 and took part in the trial which helped to establish its licence.
He said: 'This new tablet is very exciting and a double dose of good news for MS patients.
'Patients love it because it's a pill and we like it because it's a more effective pill - twice as effective as a standard therapy.
- 1 Greater Anglia application to demolish train station building thrown out
- 2 Load of Bull! Anger as Red Bull ramps up threat against Norwich gin firm
- 3 It's going down! Demolition of car showroom begins to make way for homes
- 4 'How I made four million flipping council houses into luxury student digs'
- 5 What is this mystery tower that has sprung up in Norwich?
- 6 Drunk student crashed into hotel wall after drinking tequilas
- 7 Two Norwich shops named among UK's best independent stores
- 8 Doctors baffled by teenager's horrific long Covid symptoms
- 9 REVEALED: Hotspots in Norwich with the most burglaries
- 10 Woman hunts venue for 200 people and Madness tribute after The Talk shuts
'This is at least as significant as when injection therapies first came in 15 years ago.'
The drug can be given to patients whose condition is not being controlled by self-administered injections of beta interferon or glatiramer acetate.
It fills a gap between initial treatment and once-monthly infusions of a powerful antibody drug, natalisumab, that can have serious side effects.
Draft guidance on fingolimod will be issued next month by the National Institute for Health and Clinical Excellence (Nice) which assesses the cost effectiveness of new treatments.
Its recommendations will largely decide the extent to which the drug is made freely available to NHS patients in England.
At the moment the drug will only be available on the NHS by indidivual funding requests, which are made by a consultant to the local primary care trust on the basis that there is some unusual or unique clinical factor and the case is exceptional.
PCTs consider these requests on a case-by-case basis, and Dr Lee said he hoped to be making a few applications for patients.
Treating one patient with fingolimod for a year is estimated to cost �19,665, compared with �21,257 for natalisumab.
MS occurs when the body's own immune system destroys the fatty myelin that protects and insulates nerve fibres.
Loss of myelin disrupts nerve transmissions and can lead to symptoms ranging from mild tingling sensations to serious paralysis.
MS affects around 100,000 people in Britain, and relapses requiring hospitalisation cost the NHS more than �3,000 per episode.
Fingolimod, marketed as Gilenya, is said to halve relapse rates among patients with an active form of the disease.